CRISPR Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results


You May Also Like

Elsalys Biotech : New studies confirm anti-CD160 potential in ophthalmology

New studies confirm anti-CD160 antibodies are potential therapeutics for ophthalmic diseases Efficacy and safety ...

Insmed to Present at Two October Conferences

BRIDGEWATER, N.J., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical ...